Shots:

• The TRANSFORM study (N=184; r/r LBCL) of Breyanzi vs SoC showed 29.5mos. vs 2.4mos. EFS; 45.8% vs 19.1% EFS rate at 36mos.; 87% (74% CR) vs 49% (43% CR) ORR; DoR not attained vs 9.1mos. & PFS not attained vs 6.2mos. with 50.9% vs 26.5% PFS rate at 36mos. Patient centric trial (N=61), not attained mOS with 62.8% vs 51.8% OS rate at 36mos.
• In the TRANSCEND NHL 001 study’s MCL arm, Breyanzi had a similar ORR, CR, mDoR, PFS & OS, incl. in heavily pretreated patients with most of the benefit among those with 2-4 prior therapies & shorter DoR in those with >5 prior therapies & refractory to BTK inhibitors
• The TRANSCEND FL study (for r/r FL) subgroup analysis, based on bridging therapy status, showed 93% (N=45) vs 99% (N=79) ORR with & without bridging therapy, respectively; 93% vs 95% CR rates; mDoR, PFS & OS not attained at 18.9mos. follow-up; published in Nature Medicine

Ref: BMS | Image: BMS

Related News:- BMS Reports the US FDA’s Approval of Breyanzi for Treating Mantle Cell Lymphoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com